Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration a...
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology’s molecules can quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment.

List your booth number for exhibitions, ask us